---
title: "In the report, GOLDEN THROAT's annual net profit is 251 million RMB, a decrease of 21.2%, with a final dividend of 34 Hong Kong cents"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/280909668.md"
description: "GOLDEN THROAT announced its 2025 annual performance, with revenue of 943 million RMB, a year-on-year decrease of 20.4%; gross profit of 717 million RMB, down 19.8%. It recorded a net profit of 251 million RMB, a decline of 21.2%, with earnings per share of 33.98 cents. The final dividend is 34 Hong Kong cents, compared to 50 Hong Kong cents in the same period last year"
datetime: "2026-03-29T12:14:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280909668.md)
  - [en](https://longbridge.com/en/news/280909668.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280909668.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/280909668.md) | [繁體中文](https://longbridge.com/zh-HK/news/280909668.md)


# In the report, GOLDEN THROAT's annual net profit is 251 million RMB, a decrease of 21.2%, with a final dividend of 34 Hong Kong cents

GOLDEN THROAT (06896.HK) announced its performance for the fiscal year 2025, with revenue of RMB 943 million, a year-on-year decrease of 20.4%; gross profit of RMB 717 million, down 19.8%. It recorded a net profit of RMB 251 million, a decline of 21.2%, with earnings per share of 33.98 cents. The final dividend is set at HKD 0.34, compared to HKD 0.50 in the same period last year

### 相关股票

- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md)
- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-CN/quote/513700.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-CN/quote/159929.CN.md)
- [GOLDEN THROAT (06896.HK)](https://longbridge.com/zh-CN/quote/06896.HK.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md)
- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-CN/quote/589720.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-CN/quote/159316.CN.md)

## 相关资讯与研究

- [Golden Throat Profit Falls Over 20% in 2025 but Dividend Maintained](https://longbridge.com/zh-CN/news/280842508.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/zh-CN/news/281343251.md)
- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-CN/news/281054154.md)
- [Grand Pharmaceutical Lifts Revenue, Boosts Innovative Mix Amid Margin Pressure](https://longbridge.com/zh-CN/news/280678162.md)
- [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/zh-CN/news/281068292.md)